Focused On-demand Library for Ribitol-5-phosphate xylosyltransferase 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y2B1

UPID:

RXLT1_HUMAN

Alternative names:

Transmembrane protein 5; UDP-D-xylose:ribitol-5-phosphate beta1,4-xylosyltransferase

Alternative UPACC:

Q9Y2B1; A8K017; Q6PKD6

Background:

Ribitol-5-phosphate xylosyltransferase 1, also known as Transmembrane protein 5 and UDP-D-xylose:ribitol-5-phosphate beta1,4-xylosyltransferase, plays a crucial role in the biosynthesis of phosphorylated O-mannosyl trisaccharide. This process is essential for the formation of a carbohydrate structure in alpha-dystroglycan, which is pivotal for high-affinity binding to laminin G-like domain-containing extracellular proteins.

Therapeutic significance:

The protein's involvement in Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A10, a severe disorder leading to early life mortality, underscores its therapeutic significance. Targeting the protein's pathway could offer novel treatment avenues for this and related conditions.